RxDoctor Payments Data

Michael Goldfarb, MD

Dermatology · Dearborn, MINPI 1467422923

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by UCB, Inc. at 40.6% of the total. That places this record below the midpoint for dermatology clinicians in MI, where the typical reported total is $2,933.

$3,089in general payments, 2019–2025

Across 44 payments — averaging $70.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Astrazeneca UK Limited$851
  • Sanofi$245
  • Dermavant Sciences, Inc.$230
  • Johnson & Johnson$146
  • Boehringer Ingelheim$73
  • plus $289 from 10 others
$529,105in research payments, 2019–2025

Across 118 payments — averaging $4483.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$206K
  • Takeda Pharmaceuticals U.S.A., Inc.$199K
  • Janssen Research & Development, LLC$113K
  • E.r. Squibb & Sons, L.L.C.$10K
  • Regeneron$981

What the payments were for

  • Consulting fees$1,12036%
  • Speaking & faculty fees$2458%
  • Travel & lodging$59619%
  • Food & beverage$96631%
  • Education$1625%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,089 in reported general payments places this provider in the 50th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$166,756
Medicare patients
610
Services billed
3,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab20$104,459
Calcipotriene28$6,917
Clobetasol Propionate184$6,019
Metronidazole86$3,493
Ketoconazole206$3,230
Mometasone Furoate204$3,083
Clindamycin Phosphate68$1,630
Desonide54$1,477
Ammonium Lactate73$1,391
Mupirocin185$1,390
Fluorouracil21$1,140
Azelaic Acid15$1,137
Halobetasol Propionate22$1,040
ValacyclovirValacyclovir Hcl57$1,035
Triamcinolone Acetonide77$831

Paid to pharmacies, not to this prescriber.

Other dermatology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →